Study: Subcutaneous Injectable Risperidone Improves Outcomes for Certain Patients With Schizophrenia
November 16th 2021The trial randomized patients to receive TV-46000 once monthly, TV-46000 once every 2 months, or placebo, and found that patients had improved outcomes on TV-46000 regardless of dosing schedule.
Read More
Combination of Casirivimab, Imdevimab Provides Long-Term Protection Against COVID-19
November 10th 2021A single 1200 mg subcutaneous dose of casirivimab and imdevimab (Regen-COV, Regeneron Pharmaceuticals), a preventative COVID-19 treatment, reduced the risk of contracting COVID-19 by 81.6% during months 2-8, according to additional results from a phase 3 trial published in The New England Journal of Medicine.
Read More
Study: Language Learning Associated With Cognitive Benefits for Older Adults
November 9th 2021The investigators found that older adults who studied Spanish had similar improvements to critical cognitive skills as those engaged in brain training activities specifically targeting those skills.
Read More
Microbiome Therapeutic Demonstrates Reduction of C. Difficile Recurrence
November 8th 2021SER-109, an investigational, oral, biologically-sourced microbiome therapeutic designed to reduce recurrence of C. difficile infection (CDI), demonstrated a 31.1% absolute reduction in the rate of CDI recurrence over 12 weeks compared to placebo
Read More
Study: 3% of Cancers In the US Preventable Through Weekly Physical Activity
November 2nd 2021Study finds that 16.9% of stomach cancers, 11.9% of endometrial cancers, 11.0% of kidney cancers, 9.3% of colon cancers, 8.1% of esophageal cancers, 6.5% of female breast cancers, and 3.9% of urinary bladder cancers were associated with a low level of exercise.
Read More